Life Science News

Medtronic announces results showing meaningful pain relief using DTM Spinal Cord Stimulation endurance therapy

DTM™ SCS endurance therapy enables long-lasting recharge-free performance on Vanta™ and 5-minute recharge on Intellis™ neurostimulators

- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced three-month results from an on-label, prospective, multi-center study 1 showing meaningful pain relief using DTM™ SCS endurance therapy, a modified, lower-energy variation of the company's Differential Target Multiplexed™ (DTM) Spinal Cord Stimulation (SCS) therapy for chronic overall, back or leg pain. At 3 months, patients treated with DTM SCS endurance therapy reported meaningful pain relief as measured by a 3.9 cm reduction in overall pain on the 10 cm Visual Analog Scale (VAS) 2 . Patients also reported an average 4.3 cm decrease in back pain, and an average 5.0 cm decrease in leg pain.

The Visual Analog Scale (VAS) is a widely used and accepted measure for pain intensity that captures patient-reported pain levels on a scale of 0-10. These 3-month results are consistent with those of a prior feasibility study 3 and add to the body of DTM SCS evidence demonstrating that DTM SCS endurance therapy can provide effective pain relief along with additional quality of life and functional benefits for patients.

Additional 3-month data include:

  • 69% of patients improved to a less disabled category as measured by the Oswestry Disability Index, with 63% having minimal or moderate disability at 3-months compared to just 16% at baseline
  • 75% of patients were very satisfied or somewhat satisfied with their therapy at 3-months

Modeling based on actual three-month data also shows that DTM SCS endurance therapy enables between 5.5-7.5 years device longevity when programmed on the Vanta™ recharge-free neurostimulator. 4 For those in need of a rechargeable device, DTM SCS endurance therapy programmed on the Intellis™ rechargeable neurostimulator allows either rapid recharge (5 minutes per day) or recharges of approximately one hour every 12 days. 4

"These 3-month results are highly encouraging, as they demonstrate that the DTM SCS endurance therapy may be able to provide effective pain relief while dosing at lower energy than other SCS waveforms. This may improve device longevity and offers validation of therapy for the patients who would need it," said Dr. Kasra Amirdelfan , director of Clinical Research at IPM Medical Group, Inc. and principal investigator on the DTM-LE Trial.

"Every patient with chronic pain has their own unique needs, and Medtronic is committed to offering solutions that personalize care for our patients," said Charlie Covert , vice president and general manager, Pain Therapies within the Neuromodulation business, which is part of the Neuroscience Portfolio at Medtronic. "For many, especially those who need or prefer a recharge-free SCS solution, our new DTM SCS endurance therapy offers meaningful clinical benefits by reducing pain, improving quality of life, and offering meaningful device longevity."

Enrolled patients will have additional follow-up assessments at 6 and 12 months.

These data were first shared at the 25 th Annual North American Neuromodulation Society (NANS) Annual Meeting, January 13-15 2022 .

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland , is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE: MDT), visit www.Medtronic.com and follow @Medtronic on Twitter and LinkedIn .

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

References

1 Using the Intellis™ with AdaptiveStim™ neuromodulation system

2 Peacock, Provenzano, Fishman, et al. A Prospective Multi-Center Study of a Differential Target Multiplexed™ Stimulation Derivative in Therapy-Naive Patients: Primary Endpoint and 3-Month Outcomes. Poster presented at: North American Neuromodulation Society (NANS) Annual Meeting; Jan. 13-15, 2022 ; Orlando, FL.

3 Fishman M, Hatheway J, Will A, et al. Utilization of Different Energy Profiles of Differential Target Multiplexed Spinal Cord Stimulation. American Society of Pain & Neuroscience (ASPN); July 22-25, 2021 ; Miami, FL. Poster.

4 Provenzano, Amirdelfan, Grewal, et al. Modeling Energy Demands of a Reduced-Energy Derivative of Differential Target Multiplexed™ Stimulation on Rechargeable and Recharge-free Systems. Poster presented at North American Neuromodulation Society (NANS); January 13-15, 2022 ; Orlando, FL.

Contacts:

Jeff Trauring

Ryan Weispfenning

Public Relations

Investor Relations

+1-763-505-0159

+1-763-505-4626

(PRNewsfoto/Medtronic plc)

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/medtronic-announces-results-showing-meaningful-pain-relief-using-dtm-spinal-cord-stimulation-endurance-therapy-301461012.html

SOURCE Medtronic plc

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/January2022/14/c7086.html

News Provided by Canada Newswire via QuoteMedia

MDT
Energy Fuels Announces Q2-2022 Results, Including Continued Robust Balance Sheet and Market-Leading U.S. Uranium & Rare Earth Positions

Energy Fuels Announces Q2-2022 Results, Including Continued Robust Balance Sheet and Market-Leading U.S. Uranium & Rare Earth Positions

Webcast on August 9, 2022

Energy Fuels Inc. (NYSE: UUUU) (TSX: EFR) ("Energy Fuels" or the "Company") today reported its financial results for the quarter ended June 30, 2022 . The Company's quarterly report on Form 10-Q has been filed with the U.S. Securities and Exchange Commission (" SEC ") and may be viewed on the Electronic Document Gathering and Retrieval System (" EDGAR ") at www.sec.govedgar.shtml on the System for Electronic Document Analysis and Retrieval (" SEDAR ") at www.sedar.com and on the Company's website at www.energyfuels.com . Unless noted otherwise, all dollar amounts are in U.S. dollars.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Energy Fuels Announces Q1-2022 Results, Including Continued Robust Balance Sheet, Market-Leading U.S. Uranium Position & Rare Earth Production

Energy Fuels Announces Q1-2022 Results, Including Continued Robust Balance Sheet, Market-Leading U.S. Uranium Position & Rare Earth Production

Webcast on May 18, 2022

Energy Fuels Inc. (NYSE: UUUU) (TSX: EFR) ("Energy Fuels" or the "Company") today reported its financial results for the quarter ended March 31, 2022 . The Company's annual report on Form 10-K has been filed with the U.S. Securities and Exchange Commission (" SEC ") and may be viewed on the Electronic Document Gathering and Retrieval System (" EDGAR ") at www.sec.govedgar.shtml on the System for Electronic Document Analysis and Retrieval (" SEDAR ") at www.sedar.com and on the Company's website at www.energyfuels.com . Unless noted otherwise, all dollar amounts are in U.S. dollars.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Energy Fuels Announces 2021 Results, Including Net Profits, Strong Cash Position, and Market-Leading U.S. Uranium, Rare Earth and Vanadium Position

Energy Fuels Announces 2021 Results, Including Net Profits, Strong Cash Position, and Market-Leading U.S. Uranium, Rare Earth and Vanadium Position

Webcast on March 17, 2022

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) ("Energy Fuels" or the "Company") today reported its financial results for the year ended December 31, 2021 . The Company's annual report on Form 10-K has been filed with the U.S. Securities and Exchange Commission (" SEC ") and may be viewed on the Electronic Document Gathering and Retrieval System (" EDGAR ") at www.sec.govedgar.shtml on the System for Electronic Document Analysis and Retrieval (" SEDAR ") at www.sedar.com and on the Company's website at www.energyfuels.com . Unless noted otherwise, all dollar amounts are in U.S. dollars.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Cloud DX's Post-Surgical Monitoring Wearable Validated in Peer-Reviewed Study

Cloud DX's Post-Surgical Monitoring Wearable Validated in Peer-Reviewed Study

Cloud DX's Post-Surgical Monitoring Wearable Validated in Peer-reviewed Study For the ~800,000 1 Canadian surgery patients per year, continuous monitoring with Vitaliti™ could enable earlier intervention in cases of patient decline.

  • Validation of Cloud DX's Vitaliti™ continuous monitoring device clears way for regulatory approval starting in 2022.
  • Accurate continuous data collection supports earlier detection of changes in patient condition, enabling rapid interventions to improve patient outcomes.
  • Clear opportunity to impact up to ~800,000 1 surgical patients per year in Canada, deliverable through recent partnership with medical technology leader Medtronic.

Cloud DX (TSXV:CDX)(OTCQB:CDXFF), Leading Virtual Care Platform Cloud DX has announced publication of an independent peer-reviewed validation study of its unique Vitaliti™ product, a non-invasive wearable devices that provides continuous vital sign monitoring (CVSM) device. The study assessed regulatory compliance and post-surgery use in monitoring patients' vital signs in real-world conditions. The study found Vitaliti™ to be fully ISO 81060-2:2018 compliant for the continuous vital measurement, clearing the way for regulatory approval starting in 2022. The study also found that patients welcomed the comfortable, easy to use device. Instead of care teams taking vitals periodically after surgery, Cloud DX's Vitaliti™ was used for continuous monitoring, which could transform post-surgical care by enabling early detection if any deterioration occurs in patient health. On launch, Vitaliti™ will become a key component of Cloud DX's Connected Health™ ecosystem of remote monitoring technologies. Through Cloud DX's recent partnership with Medtronic Canada ULC (a subsidiary of Medtronic plc (MDT), a global leader in healthcare technology), wide deployment of Vitaliti™ is intended to initially improve post-operative care for surgical patients in Canada (up to 800,000 annually) and eventually in the United States (up to several million annually

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
InvestmentPitch Media Video Discusses Cloud DX's Selection by Medtronic for Canada-Wide Remote Patient Monitoring - Video Available on Investmentpitch.com

InvestmentPitch Media Video Discusses Cloud DX's Selection by Medtronic for Canada-Wide Remote Patient Monitoring - Video Available on Investmentpitch.com

Cloud DX Inc. (TSXV: CDX) (OTCQB: CDXFF) has been selected by Medtronic Canada ULC, to provide world-class virtual healthcare to Medtronic's patients across Canada. Medtronic Canada, (www.medtronic.ca) headquartered in Brampton, Ontario, with regional offices in Montreal and Vancouver, is the largest medical technology company in Canada, and a subsidiary of Medtronic plc (NYSE: MDT), a multi billion-dollar, global leader in medical technology, offering medical devices and therapies to more than 72 million people across 150 countries.

For more information, please view the InvestmentPitch Media "video" which provides additional information about this news and the company, along with comments from Robert Kaul, CEO of Cloud DX, about the significance of this news. If this link is not enabled, please visit www.InvestmentPitch.com and enter "Cloud DX" in the search box.

This partnership advances Medtronic's commitment to improving patient outcomes and lowering overall costs along the care continuum. Medtronic Canada delivers care in a broad range of clinical areas, including spinal and cardiac surgeries, cardiology, critical care, diabetes, vascular and renal care. Most clinical areas are expected to improve patient outcomes and satisfaction with some aspect of virtual care in the future.

Cloud DX's Connected Health™ remote patient monitoring platform is used by healthcare enterprises and care teams across North America to virtually manage chronic disease, enable aging in place, and deliver hospital-quality post-surgical care in the home. Its partners achieve better healthcare and patient outcomes, reduce the need for hospitalization or re-admission, and reduce healthcare delivery costs through more efficient use of resources.

Cloud DX's remote patient monitoring technology and services are exclusive to Medtronic and its Canada-wide client base. Initially, Medtronic seeks to integrate the Connected Health™ platform and associated services within both perioperative and complex chronic disease pathways in Canada.

Under the agreement, a typical deployment would involve the enrollment of a chronic care or surgical patient onto the Connected Health™ platform, generating recurring revenue, depending on the length of the monitoring program. Cloud DX generates revenue upfront for kits prescribed to patients for use at home, and then a monthly subscription fee per patient for software, services, and support. Additional revenues could also be generated through customizations, consulting, and special services, as needed.

Jessica Rudd, National Director of New Partnerships and Solutions at Medtronic Canada, stated: "Medtronic is committed to partnering with Canada-based SMEs to advance the Canadian life sciences ecosystem. More importantly, Medtronic Canada is dedicated to responding to the needs of our Canadian healthcare system, and we are committed to enabling equitable access to care and patient empowerment and reducing the burden on our precious health human resources. However, we can't do this alone. To that end, we are delighted to enter this exclusive partnership with Cloud DX and scale their innovative technology, thoughtful service model, and excellent track record for delivering results to patients across the country."

Among its many awards, Cloud DX is the co-winner of the Qualcomm Tricorder XPRIZE, a 2021 Edison Award winner, a Fast Company "World Changing Idea" finalist, and one of " Canada's Ten Most Prominent Telehealth Providers.

The shares are trading at $0.195. For more information, please visit the company's corporate website www.CloudDX.com, and the company's investor relation site ir.CloudDX.com/overview/default.aspx, contact Jay Bedard, Investor Relations, at 647-881-8418 or by email at jay.bedard@CloudDX.com.

About InvestmentPitch Media

Investmentpitch Media leverages the power of video, which together with its extensive distribution, positions a company's story ahead of the 1,000's of companies seeking awareness and funding from the financial community. The company specializes in producing short videos based on significant news releases, research reports and other content of interest to investors.

CONTACT:
InvestmentPitch Media
Barry Morgan, CFO
bmorgan@investmentpitch.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/106272

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Abbott Reports Fourth-Quarter and Full-Year 2022 Results; Issues 2023 Financial Outlook

  • Fourth-quarter sales of $10.1 billion ; full-year 2022 sales of $43.7 billion
  • Full-year 2022 sales growth of 1.3 percent; organic sales growth of 6.4 percent
  • Full-year 2022 GAAP diluted EPS of $3.91 ; adjusted diluted EPS of $5.34
  • Continues to strengthen portfolio with steady cadence of new product approvals

Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2022 .

  • Fourth-quarter sales of $10.1 billion , which were negatively impacted by an expected year-over-year decline in COVID-19 testing-related sales, decreased 12.0 percent on a reported basis and 6.1 percent on an organic basis, which excludes the impact of foreign exchange.
  • Excluding COVID-19 testing-related sales 1 , fourth-quarter sales decreased 1.4 percent on a reported basis and increased 5.4 percent on an organic basis.
  • Excluding COVID-19 testing-related sales 2 and U.S. infant formula sales that were impacted by manufacturing disruptions 3 , full-year 2022 sales increased 1.9 percent on a reported basis and 7.4 percent on an organic basis.
  • GAAP diluted EPS was $0.59 in the fourth quarter. Excluding specified items, adjusted diluted EPS was $1.03 .
  • Abbott issues full-year 2023 guidance for diluted EPS from continuing operations on a GAAP basis of $3.05 to $3.25 and full-year adjusted EPS from continuing operations of $4.30 to $4.50 .
  • Abbott projects full-year 2023 organic sales growth, excluding COVID-19 testing-related sales, of high-single digits 4 and COVID-19 testing-related sales of around $2.0 billion .
  • In October, Abbott's market-leading FreeStyle Libre ® continuous glucose monitoring system was named the "Best Medical Technology" of the last 50 years by the Galien Foundation.
  • In December, Abbott announced U.S. Food and Drug Administration (FDA) approval of its Eterna™ spinal cord stimulation system — the smallest implantable, rechargeable system currently available for the treatment of chronic pain. 5
  • In January, Abbott announced U.S. FDA approval of its minimally invasive Navitor™ transcatheter aortic valve implantation (TAVI) system for people with severe aortic stenosis who are at high risk for surgery.

"We significantly exceeded the EPS guidance we provided at the beginning of last year despite challenging global business conditions," said Robert B. Ford , chairman and chief executive officer, Abbott. "Our R&D pipeline continues to be highly productive with several recent and upcoming new product launches that position us well going forward."

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Singular Health Group Limited

Completion of Global3D Acquisition

Medical technology company Singular Health Group Ltd (ASX: SHG) (“Singular Health”, or “the Company”) is pleased to advise that it has completed the acquisition of the assets of Global3D Pty Ltd (“Global3D”) as previously announced on 6 December 2022. The acquisition is the culmination of over two years of working together with Global3D to investigate and develop enhanced software, technology and 3D printing processes for a range of medical devices, including customised ankle foot orthotics and individualised prosthetics.

Keep reading...Show less

Johnson & Johnson Reports Q4 and Full-Year 2022 Results

  • 2022 Fourth-Quarter reported sales decline of 4.4% to $23.7 Billion primarily driven by unfavorable foreign exchange and reduced COVID-19 Vaccine sales vs. prior year. Operational growth excluding COVID-19 Vaccine of 4.6%*
  • 2022 Fourth-Quarter earnings per share (EPS) of $1.33 decreasing 24.9% and adjusted EPS of $2.35 increasing by 10.3%*
  • 2022 Full-Year reported sales growth of 1.3% to $94.9 Billion primarily driven by strong commercial execution partially offset by unfavorable foreign exchange. Operational growth of 6.1%*
  • 2022 Full-Year earnings per share (EPS) of $6.73 decreasing 13.8% and adjusted EPS of $10.15 increasing by 3.6%*
  • Company guides 2023 adjusted operational sales growth excluding COVID-19 Vaccine of 4.0%* and adjusted operational EPS of $10.50, reflecting growth of 3.5%*

Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2022. "Our full year 2022 results reflect the continued strength and stability of our three business segments, despite macroeconomic challenges," said Joaquin Duato, Chairman of the Board and Chief Executive Officer. "I am inspired by our employees who make a difference in the health and lives of people around the world every day. As we look ahead to 2023, Johnson & Johnson is well-positioned to drive near-term growth, while also investing strategically to deliver long-term value."

OVERALL FINANCIAL RESULTS